Latest News

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Aug

25

2021

Senhwa’s Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Aug

17

2021

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

Aug

16

2021

Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib

Aug

11

2021

Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment

Jun

23

2021

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Sep

27

2021

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial of Silmitasertib as a Treatment for Patients with Severe COVID-19.

Jan

22

2021

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data.

Jan

15

2021